Oregon Public Employees Retirement Fund boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 1.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,652,936 shares of the biopharmaceutical company’s stock after acquiring an additional 19,989 shares during the period. Pfizer accounts for about 1.0% of Oregon Public Employees Retirement Fund’s investment portfolio, making the stock its 8th largest position. Oregon Public Employees Retirement Fund’s holdings in Pfizer were worth $59,010,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer during the second quarter valued at approximately $102,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer during the second quarter valued at approximately $103,000. D. Scott Neal Inc. raised its position in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $120,000. Finally, Lipe & Dalton raised its position in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 300 shares during the last quarter. Institutional investors own 69.75% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) opened at $36.99 on Friday. Pfizer Inc. has a 52-week low of $30.90 and a 52-week high of $37.37. The firm has a market capitalization of $220,490.00, a price-to-earnings ratio of 22.69, a PEG ratio of 2.31 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.68%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is 78.53%.
Pfizer announced that its board has authorized a stock repurchase plan on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.
A number of research analysts recently weighed in on PFE shares. Nord/LB reissued a “neutral” rating on shares of Pfizer in a report on Wednesday, December 27th. Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Goldman Sachs Group set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, November 1st. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, December 15th. Finally, Jefferies Group set a $39.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. Pfizer currently has an average rating of “Buy” and an average target price of $38.94.
In other news, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at $3,827,946. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,450 shares of company stock valued at $1,065,220. Corporate insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Oregon Public Employees Retirement Fund Grows Holdings in Pfizer Inc. (PFE)” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://sportsperspectives.com/2018/01/19/oregon-public-employees-retirement-fund-grows-holdings-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.